The global laboratory developed tests market was valued at USD 42.40 billion in 2025. The market is estimated at USD 46.20 billion in 2026 and is projected to reach USD 108.60 billion by 2036, at a CAGR of 8.9% during the forecast period 2026-2036. This report assesses the regulatory and oversight landscape, reimbursement, test validation and quality, the value chain, pricing and reimbursement rates, the competitive landscape, and future growth opportunities.
The market covers clinical testing revenue from assays that a laboratory designs, validates, and runs in its own facility instead of buying an approved kit from a diagnostics manufacturer. Methods include PCR and digital PCR, next-generation sequencing (NGS), immunoassays and other protein tests, mass spectrometry, flow cytometry, cytogenetic analysis, and algorithm-based multi-analyte assays. Approved kits sold by manufacturers, laboratory instruments and reagents, research-use-only testing, consumer genetic tests not ordered by a clinician, and routine anatomic pathology are excluded.
In the U.S., the FDA final rule of May 2024, which would have brought laboratory developed tests under device regulation, was struck down in March 2025 by a federal district court in Texas; no appeal followed, and in August 2025 the FDA signaled that it would rescind the rule. Oversight therefore rests mainly on Clinical Laboratory Improvement Amendments (CLIA) requirements and accreditation, and the College of American Pathologists has aligned its accreditation checklists with revised CLIA rules that took effect in December 2024. Guardant Health reported about 66,000 Shield blood-based screening tests in the second quarter of 2026, up from about 16,000 a year earlier, while Natera reported about 296,700 oncology tests in the same quarter, up 57.2% year over year.
Reimbursement has replaced regulation as the main commercial constraint, since coverage needs published evidence of clinical utility, guideline inclusion, and payer-by-payer engagement that can take years. Myriad Genetics reported that its hereditary cancer testing volume rose 8% in the second quarter of 2026 while revenue in that business fell 13% on lower reimbursement. Policy risk also lingers, as legislative proposals for federal oversight of diagnostic tests have been introduced repeatedly. Further challenges include result differences between laboratories running similar assays, shortages of laboratory scientists and genetic counselors, and the fixed cost of keeping large test menus validated.
Molecular residual disease and recurrence monitoring at scale, multi-cancer and blood-based early detection, and AI-enabled interpretation and data services are the main opportunities, with Tempus AI having reported 28% growth in its Data and Applications revenue in the second quarter of 2026. Specialty testing in Asia-Pacific and Europe also offers long-term growth, especially where national genomics programs channel testing to selected laboratories. Key trends include the shift from single-event diagnosis to longitudinal monitoring, the convergence of laboratory testing with data and AI platforms, and the acquisition of specialty capabilities by national reference laboratories such as Quest Diagnostics and Labcorp.
By technology, the laboratory developed tests market is segmented into molecular diagnostics (other molecular methods, PCR & digital PCR, and next-generation sequencing), immunoassay & protein-based testing, mass spectrometry, flow cytometry & cytogenetics, and other technologies. The largest share in 2026 is expected to go to molecular diagnostics, as molecular methods dominate oncology, hereditary, reproductive, and infectious disease testing, fast-changing evidence favors in-house assays, and most specialty laboratory growth is molecular. Within molecular diagnostics, next-generation sequencing is projected to grow the fastest, supported by growing use of genomic profiling, residual disease monitoring, rare disease sequencing, and screening. Mass spectrometry is expected to grow steadily in endocrine and drug monitoring tests that lack approved kits.
By application, the laboratory developed tests market is segmented into oncology (therapy selection & companion testing and comprehensive genomic profiling), molecular residual disease & early cancer detection, hereditary & rare disease, reproductive & prenatal health, infectious disease, pharmacogenomics, and other applications. Oncology is expected to account for the largest share in 2026, reflecting high genomic profiling volumes, more biomarker-driven therapies, high reimbursed value per test, and the need to update gene content as evidence evolves. Molecular residual disease & early cancer detection is projected to record the highest CAGR, because monitoring tests recur over time, screening populations are very large, leading laboratories are reporting rapid volume gains, and national reference laboratories are entering the category.
By laboratory type, the laboratory developed tests market is segmented into specialty & molecular reference laboratories, national clinical laboratories, academic medical center & non-profit reference laboratories, and hospital & health system laboratories. Specialty & molecular reference laboratories are expected to hold the largest share in 2026, since high-value genomic testing is concentrated in franchise-focused laboratories, companies such as Natera, Guardant Health, and Tempus have reached significant scale, and these laboratories invest heavily in evidence and payer engagement. Hospital & health system laboratories are projected to grow at the highest CAGR, as hospitals bring molecular testing in house to shorten turnaround and keep margin, sequencing platforms are becoming more affordable, and in-house testing links directly with health system oncology and genetics services. For rare and ultra-rare conditions, most testing still comes from non-profit and academic centers such as ARUP and Mayo Clinic Laboratories.
By test volume category, the laboratory developed tests market is segmented into high-volume routine tests, specialty tests, and rare & ultra-rare disease tests. Specialty tests are expected to account for the largest share in 2026 and to grow at the highest CAGR during the forecast period, because oncology, hereditary cancer, reproductive, and monitoring tests fall in this group and carry high reimbursed value, while routine assays are mostly served by approved kits. Rare & ultra-rare disease tests hold a modest share of revenue despite their clinical importance because individual volumes are very low, and growth in high-volume routine tests is expected to stay slow given kit availability and price competition.
By end user, the laboratory developed tests market is segmented into hospitals & health systems, physician offices & specialty clinics, pharmaceutical & biotechnology companies, and other end users such as direct-access testing, employers, and government programs. Hospitals & health systems are expected to account for the largest share in 2026, measured by the setting that orders the test, as oncology, rare disease, and inpatient testing are concentrated there and tumor boards and specialist clinics play a central role in ordering advanced molecular tests. Pharmaceutical & biotechnology companies are projected to record the highest CAGR, driven by trial patient selection, companion testing ahead of approved kits, and demand for laboratory data services.
North America is expected to lead the global laboratory developed tests market in 2026, owing to the CLIA framework, which gives laboratories an established way to validate and offer in-house assays, well-funded specialty laboratories, Medicare and commercial coverage of advanced tests, and the high level of U.S. cancer genomics and screening activity. Europe holds a significant position, supported by academic and national laboratory capacity, genomic medicine programs, and provisions that allow health institutions to make and use in-house devices under set conditions. However, the In Vitro Diagnostic Regulation tightens the rules for in-house assays whenever a comparable approved device is on the market, leading some European laboratories to review their test menus.
Asia-Pacific is expected to be the fastest-growing region through 2036, driven by fast uptake of cancer genomic and hereditary testing across China, Japan, South Korea, and India, government-backed genomics programs, more specialty and hospital laboratory capacity, and domestic sequencing capability that reduces reliance on imported kits. Smaller shares are held by Latin America and the Middle East & Africa; oncology and reproductive testing support demand in Brazil and Mexico, while national genome programs and investment in specialty laboratories in the Gulf countries support growth in Saudi Arabia and the UAE.
Competition in the laboratory developed tests market is spread across many players, yet within each test category a handful of laboratories usually handle most of the volume. Laboratories compete on clinical evidence, payer coverage, guideline status, turnaround, menu breadth, physician relationships, and the quality of interpretive reports. Leading laboratories are funding evidence studies, extending from diagnosis to monitoring and screening, adding data and AI offerings, and buying specialty capabilities. Recent developments include rapid growth in Shield screening volumes at Guardant Health and New York State approval of Quest Diagnostics' Haystack molecular residual disease test.
Key companies profiled in the report include Laboratory Corporation of America Holdings (U.S.), Quest Diagnostics Incorporated (U.S.), Natera, Inc. (U.S.), Guardant Health, Inc. (U.S.), Exact Sciences Corporation (U.S.), Tempus AI, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), NeoGenomics, Inc. (U.S.), Fulgent Genetics, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Foundation Medicine) (Switzerland), ARUP Laboratories (U.S.), and Mayo Clinic Laboratories (U.S.).
The market covers clinical testing revenue from assays that a laboratory designs, validates, and runs in its own facility instead of buying an approved kit from a diagnostics manufacturer. Methods include PCR and digital PCR, next-generation sequencing (NGS), immunoassays and other protein tests, mass spectrometry, flow cytometry, cytogenetic analysis, and algorithm-based multi-analyte assays. Approved kits sold by manufacturers, laboratory instruments and reagents, research-use-only testing, consumer genetic tests not ordered by a clinician, and routine anatomic pathology are excluded.
In the U.S., the FDA final rule of May 2024, which would have brought laboratory developed tests under device regulation, was struck down in March 2025 by a federal district court in Texas; no appeal followed, and in August 2025 the FDA signaled that it would rescind the rule. Oversight therefore rests mainly on Clinical Laboratory Improvement Amendments (CLIA) requirements and accreditation, and the College of American Pathologists has aligned its accreditation checklists with revised CLIA rules that took effect in December 2024. Guardant Health reported about 66,000 Shield blood-based screening tests in the second quarter of 2026, up from about 16,000 a year earlier, while Natera reported about 296,700 oncology tests in the same quarter, up 57.2% year over year.
Market Dynamics
Speed to clinical use is a major driver of the laboratory developed tests market. A qualified laboratory can build and validate an assay for a newly actionable biomarker within months, while a manufacturer needs far longer to win kit clearance and does so only for large markets, so this is how most new molecular tests, and nearly all rare disease tests, get to patients. Precision oncology adds strong demand, as comprehensive genomic profiling is standard for many advanced cancers and molecular residual disease monitoring creates repeat testing for each patient over years. Blood-based screening reaches eligible populations in the tens of millions and can scale quickly once guideline support and coverage are in place, while for most of the thousands of rare and ultra-rare conditions no approved test exists.Reimbursement has replaced regulation as the main commercial constraint, since coverage needs published evidence of clinical utility, guideline inclusion, and payer-by-payer engagement that can take years. Myriad Genetics reported that its hereditary cancer testing volume rose 8% in the second quarter of 2026 while revenue in that business fell 13% on lower reimbursement. Policy risk also lingers, as legislative proposals for federal oversight of diagnostic tests have been introduced repeatedly. Further challenges include result differences between laboratories running similar assays, shortages of laboratory scientists and genetic counselors, and the fixed cost of keeping large test menus validated.
Molecular residual disease and recurrence monitoring at scale, multi-cancer and blood-based early detection, and AI-enabled interpretation and data services are the main opportunities, with Tempus AI having reported 28% growth in its Data and Applications revenue in the second quarter of 2026. Specialty testing in Asia-Pacific and Europe also offers long-term growth, especially where national genomics programs channel testing to selected laboratories. Key trends include the shift from single-event diagnosis to longitudinal monitoring, the convergence of laboratory testing with data and AI platforms, and the acquisition of specialty capabilities by national reference laboratories such as Quest Diagnostics and Labcorp.
Segment Analysis
The report analyzes the market by technology, application, laboratory type, test volume category, end user, and geography, helping stakeholders identify the most attractive areas for test development, partnerships, and investment.By technology, the laboratory developed tests market is segmented into molecular diagnostics (other molecular methods, PCR & digital PCR, and next-generation sequencing), immunoassay & protein-based testing, mass spectrometry, flow cytometry & cytogenetics, and other technologies. The largest share in 2026 is expected to go to molecular diagnostics, as molecular methods dominate oncology, hereditary, reproductive, and infectious disease testing, fast-changing evidence favors in-house assays, and most specialty laboratory growth is molecular. Within molecular diagnostics, next-generation sequencing is projected to grow the fastest, supported by growing use of genomic profiling, residual disease monitoring, rare disease sequencing, and screening. Mass spectrometry is expected to grow steadily in endocrine and drug monitoring tests that lack approved kits.
By application, the laboratory developed tests market is segmented into oncology (therapy selection & companion testing and comprehensive genomic profiling), molecular residual disease & early cancer detection, hereditary & rare disease, reproductive & prenatal health, infectious disease, pharmacogenomics, and other applications. Oncology is expected to account for the largest share in 2026, reflecting high genomic profiling volumes, more biomarker-driven therapies, high reimbursed value per test, and the need to update gene content as evidence evolves. Molecular residual disease & early cancer detection is projected to record the highest CAGR, because monitoring tests recur over time, screening populations are very large, leading laboratories are reporting rapid volume gains, and national reference laboratories are entering the category.
By laboratory type, the laboratory developed tests market is segmented into specialty & molecular reference laboratories, national clinical laboratories, academic medical center & non-profit reference laboratories, and hospital & health system laboratories. Specialty & molecular reference laboratories are expected to hold the largest share in 2026, since high-value genomic testing is concentrated in franchise-focused laboratories, companies such as Natera, Guardant Health, and Tempus have reached significant scale, and these laboratories invest heavily in evidence and payer engagement. Hospital & health system laboratories are projected to grow at the highest CAGR, as hospitals bring molecular testing in house to shorten turnaround and keep margin, sequencing platforms are becoming more affordable, and in-house testing links directly with health system oncology and genetics services. For rare and ultra-rare conditions, most testing still comes from non-profit and academic centers such as ARUP and Mayo Clinic Laboratories.
By test volume category, the laboratory developed tests market is segmented into high-volume routine tests, specialty tests, and rare & ultra-rare disease tests. Specialty tests are expected to account for the largest share in 2026 and to grow at the highest CAGR during the forecast period, because oncology, hereditary cancer, reproductive, and monitoring tests fall in this group and carry high reimbursed value, while routine assays are mostly served by approved kits. Rare & ultra-rare disease tests hold a modest share of revenue despite their clinical importance because individual volumes are very low, and growth in high-volume routine tests is expected to stay slow given kit availability and price competition.
By end user, the laboratory developed tests market is segmented into hospitals & health systems, physician offices & specialty clinics, pharmaceutical & biotechnology companies, and other end users such as direct-access testing, employers, and government programs. Hospitals & health systems are expected to account for the largest share in 2026, measured by the setting that orders the test, as oncology, rare disease, and inpatient testing are concentrated there and tumor boards and specialist clinics play a central role in ordering advanced molecular tests. Pharmaceutical & biotechnology companies are projected to record the highest CAGR, driven by trial patient selection, companion testing ahead of approved kits, and demand for laboratory data services.
Regional Analysis
The report covers North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa, spanning 17 countries and four rest-of-region groups. The regional analysis of the laboratory developed tests market considers regulatory frameworks for in-house assays, reimbursement for advanced molecular testing, specialty laboratory capacity, and national genomic medicine programs.North America is expected to lead the global laboratory developed tests market in 2026, owing to the CLIA framework, which gives laboratories an established way to validate and offer in-house assays, well-funded specialty laboratories, Medicare and commercial coverage of advanced tests, and the high level of U.S. cancer genomics and screening activity. Europe holds a significant position, supported by academic and national laboratory capacity, genomic medicine programs, and provisions that allow health institutions to make and use in-house devices under set conditions. However, the In Vitro Diagnostic Regulation tightens the rules for in-house assays whenever a comparable approved device is on the market, leading some European laboratories to review their test menus.
Asia-Pacific is expected to be the fastest-growing region through 2036, driven by fast uptake of cancer genomic and hereditary testing across China, Japan, South Korea, and India, government-backed genomics programs, more specialty and hospital laboratory capacity, and domestic sequencing capability that reduces reliance on imported kits. Smaller shares are held by Latin America and the Middle East & Africa; oncology and reproductive testing support demand in Brazil and Mexico, while national genome programs and investment in specialty laboratories in the Gulf countries support growth in Saudi Arabia and the UAE.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard with market leaders, market differentiators, vanguards, and emerging players, and market share and rank analysis by key player for 2025. Company profiles include business overviews, financial overviews, test menus and franchises, reimbursement and evidence positions, strategic developments, and SWOT analyses.Competition in the laboratory developed tests market is spread across many players, yet within each test category a handful of laboratories usually handle most of the volume. Laboratories compete on clinical evidence, payer coverage, guideline status, turnaround, menu breadth, physician relationships, and the quality of interpretive reports. Leading laboratories are funding evidence studies, extending from diagnosis to monitoring and screening, adding data and AI offerings, and buying specialty capabilities. Recent developments include rapid growth in Shield screening volumes at Guardant Health and New York State approval of Quest Diagnostics' Haystack molecular residual disease test.
Key companies profiled in the report include Laboratory Corporation of America Holdings (U.S.), Quest Diagnostics Incorporated (U.S.), Natera, Inc. (U.S.), Guardant Health, Inc. (U.S.), Exact Sciences Corporation (U.S.), Tempus AI, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), NeoGenomics, Inc. (U.S.), Fulgent Genetics, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Foundation Medicine) (Switzerland), ARUP Laboratories (U.S.), and Mayo Clinic Laboratories (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global laboratory developed tests market.
- Explains how speed to clinical use, precision oncology, residual disease monitoring, and blood-based screening are driving growth.
- Assesses the effect of the vacated FDA rule, CLIA oversight, the EU In Vitro Diagnostic Regulation, and reimbursement on laboratories.
- Identifies high-growth opportunities across technology, application, laboratory type, test volume category, end user, and region.
- Tracks the shift to longitudinal monitoring and the growth of AI-enabled interpretation and data services.
- Benchmarks leading laboratories on test menus, reimbursement and evidence position, and strategic developments.
- Supports test development, reimbursement strategy, partnership, acquisition, and market entry decisions for laboratories, diagnostics companies, and investors.
Key Questions Answered
- How big is the global laboratory developed tests market today, and how will it grow through 2036?
- How has the vacatur of the FDA final rule changed the regulatory outlook for laboratory developed tests?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- Why has reimbursement become the main commercial constraint, and how are laboratories building the evidence payers require?
- Which technologies, applications, laboratory types, test volume categories, and end users will grow the fastest?
- How quickly are molecular residual disease monitoring and blood-based screening being adopted?
- How does the EU In Vitro Diagnostic Regulation affect in-house assays in Europe?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading laboratories, and what strategies are they using to strengthen their position?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Laboratory Developed Tests Market Assessment, by Technology
6. Laboratory Developed Tests Market Assessment, by Application
7. Laboratory Developed Tests Market Assessment, by Laboratory Type
8. Laboratory Developed Tests Market Assessment, by Test Volume Category
9. Laboratory Developed Tests Market Assessment, by End User
10. Laboratory Developed Tests Market Assessment, by Geography
11. Competition Analysis
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Laboratory Corporation of America Holdings
- Quest Diagnostics Incorporated
- Natera, Inc.
- Guardant Health, Inc.
- Exact Sciences Corporation
- Tempus AI, Inc.
- Myriad Genetics, Inc.
- NeoGenomics, Inc.
- Fulgent Genetics, Inc.
- F. Hoffmann-La Roche Ltd
- ARUP Laboratories
- Mayo Clinic Laboratories
